Subscribe to RSS
DOI: 10.1055/s-0042-1754380
Challenges in the Diagnosis and Treatment of Patients with Rare and Orphan Diseases
Abstract
Orphan diseases are diverse group of disorders that have not gained much of public attention as they are rarely reported worldwide. The term orphan and rare diseases are often used interchangeably when describing diseases that fall into an orphan or rare category. Around 80% of orphan diseases are chronic, serious, or life threatening, are of genetic origin, and are more prevalent in children and in adults above 40 years of age. Due to rarity, lack of financial support and specific drug to treat these diseases, diagnosis, and treatment becomes challenging. Diagnosis is usually delayed, and patient continues to suffer by seeking multiple specialist opinion. Nonavailability of specific drug and lack of financial funding or waivers to conduct to conduct clinical trial for invention of new orphan drug are the obstacles for targeted treatment. Hence, there is need for comprehensive integrative approach to manage orphan disease patients and pharmaceutical companies should be encouraged for invention of drugs at a reasonable cost for orphan diseases. In addition, community education through genetic-based learning modules is essential to increase awareness of population about risk factors and early diagnosis of orphan diseases, and to take opinion of specific specialist for thorough clinical evaluation. This review discusses challenges faced by the specialists toward diagnosis and treatment of orphan disease for well-being of an individual living with the disorder.
* Dr. Tarun Vyas is now affiliated to Department of Oral Medicine and Radiology, Vyas Dental College and Hospital, Jodhpur, Rajasthan, India.
Publication History
Article published online:
20 September 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Aronson JK. Rare diseases and orphan drugs. Br J Clin Pharmacol 2006; 61 (03) 243-245
- 2 National Organization for Rare Disorders. . [26 January 2006]. Accessed July 7, 2022 http://www.rarediseases.org/search/rdblist.html
- 3 Loizzo A, Tebano MT. Malattie orfane. [Orphan diseases] Recenti Prog Med 1993; 84 (11) 786-793
- 4 Joppi R, Bertele V, Garattini S. Orphan drug development is progressing too slowly. Br J Clin Pharmacol 2006; 61 (03) 355-360
- 5 The portal for rare diseases and orphan drugs.. https://www.orpha.net/consor/cgi-bin/index.php . [ Orphanet version 5.52.0 - Last upda ted: 2022–06–04]
- 6 Danese E, Lippi G. Rare diseases: the paradox of an emerging challenge. Ann Transl Med 2018; 6 (17) 329
- 7 de la Paz MP, Villaverde-Hueso A, Alonso V. et al. Rare diseases epidemiology research. Adv Exp Med Biol 2010; 686: 17-39
- 8 Bennett RL, Motulsky AG, Bittles A. et al. Genetic counseling and screening of consanguineous couples and their offspring: recommendations of the national society of genetic counsellors. J Genet Couns 2002; 11 (02) 97-119
- 9 Lunn MR, Stockwell BR. Chemical genetics and orphan genetic diseases. Chem Biol 2005; 12 (10) 1063-1073
- 10 Garel N, Joober R. Are mental disorders orphan diseases?. J Psychiatry Neurosci 2020; 45 (02) 75-78
- 11 Luo E, Liu H, Zhao Q, Shi B, Chen Q. Dental-craniofacial manifestation and treatment of rare diseases. Int J Oral Sci 2019; 11 (01) 9
- 12 Niida Y, Ozaki M, Inoue M. et al. CHIPS for genetic testing to improve a regional clinical genetic service. Clin Genet 2015; 88 (02) 155-160
- 13 Mason M, Levenson J, Quillin J. Direct-to-consumer genetic testing and orphan drug development. Genet Test Mol Biomarkers 2017; 21 (08) 456-463
- 14 Genetic Testing for Rare Diseases with Sequencing.com.. 2021. Accessed July 7, 2022 at https://sequencing.com/blog/post/genetic-testing-rare-diseases-sequencing
- 15 Freitas E, Zhang G. Exploration of patients' spiritual/religious beliefs and resuscitation decisions. Hawaii J Health Soc Welf 2019; 78 (07) 216-222
- 16 Alfaro TM, Wijsenbeek MS, Powell P. et al. Educational aspects of rare and orphan lung diseases. Respir Res 2021; 22 (01) 92
- 17 Sharma A, Jacob A, Tandon M, Kumar D. Orphan drug: development trends and strategies. J Pharm Bioallied Sci 2010; 2 (04) 290-299
- 18 Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. Issues surrounding orphan disease and orphan drug policies in Europe. Appl Health Econ Health Policy 2010; 8 (05) 343-350